I don't understand why you are bothered by the fact that the "higher dosage didn't show statistical significance while the lower one did".The point, which came out in last year's annual meeting, is that the company screwed up by not realizing the significance of the "frequency" of dosage, as their own research group was pointing out BEFORE last year's clinical trials. In fact, as I understand it, part of the reason the FDA is insisting on another trial this year is that the company got disparate results as a function of dosage. Now they have to run another trial to show (again) that the vaccine works if the patients take it frequently enough, i.e every other day for two weeks or whatever it works out to be in the trial.
I have been a shareholder for 6 years and I was genuinely sorry to see Malcolm Gefter leave.(His office is across the street from mine here at MIT). I must admit, however, that the last couple of years it seems that the company has been run by Howard, Fine, and Howard (also known as the 3 stooges).
Best regards |
